Search clinical trials for: asunaprevir

Total 40 results

National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

HIV-HCV

United States
Sang Gyune Kim
Bristol-Myers Squibb; Korea University; Gachon University Gil Medical Center; Seoul... and other collaborators

Unknown

Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment (RELIF-C)

Chronic Hepatitis C

Korea, Republic of
Myeong Jun Song
Bristol-Myers Squibb; Korea University Guro Hospital; Severance Hospital; Eulji... and other collaborators

Completed

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Hepatitis C

Korea, Republic of
Foundation for Liver Research

Completed

Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients (ImmunoDual)

Chronic Hepatitis C

Netherlands
Tainan Municipal Hospital

Withdrawn

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

Hepatitis c
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Kaohsiung Medical University Chung-Ho Memorial...
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Completed

Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

Hepatitis C

Taiwan
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Withdrawn

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen (QUATTROTURBO)

Hepatitis C Virus Genotype 4 Infection

France
Bristol-Myers Squibb

Completed

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C Virus Infection

Japan
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Chronic Hepatitis C

France, United States, Puerto Rico
Bristol-Myers Squibb

Completed

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Hepatitis C

United States
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders (QUADRIH)

HCV-HIV Co-Infection

France
Timothy Morgan, MD
Bristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...

Completed

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (RHACE 1)

Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir

Hepatitis C Infection
Qing XIe
Gilead Sciences; Tigermed Consulting Co., Ltd

Recruiting

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (C-DIAMOND)

Hepatitis C, Chronic

China
Bristol-Myers Squibb

Completed

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Hepatitis C

China, Korea, Republic of, Russian Federation
Bristol-Myers Squibb

Completed

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Hepatic Insufficiency

United States
Bristol-Myers Squibb

Completed

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin

Hepatitis C
Kirby Institute
Bristol-Myers Squibb

Withdrawn

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (HEPCOG-II)

Hepatitis C, Chronic

Australia
Bristol-Myers Squibb

Completed

Drug-Drug Interaction Study in Healthy Subjects

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Hepatitis C Infection

Japan
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Bristol-Myers Squibb

Completed

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Hepatitis C Virus Infection

Japan
Bristol-Myers Squibb

Completed

Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325

Hepatitis C
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Children With HIV-Related Cancer

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Leukemia

Puerto Rico, United States, Switzerland, Canada
Bristol-Myers Squibb

Completed

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Hepatitis C

United States, Australia, Canada, France
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
Bristol-Myers Squibb

Completed

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Hepatitis C Virus

France, Spain, United Kingdom, United States, Germany, Italy, Argentina, Ireland
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Chronic Hepatitis C

France, United States, Puerto Rico
Humanity and Health Research Centre
Emory University; Beijing 302 Hospital

Completed

Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects

Chronic Hepatitis C Infection

China
Bristol-Myers Squibb

Completed

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (Hallmark QUAD)

Hepatitis C Virus

United States, Germany, Italy, Korea, Republic of, Sweden, Russian Federation, Canada, France, Argentina, Switzerland, Denmark, Taiwan, Netherlands, Spain, Mexico
Bristol-Myers Squibb

Completed

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Hepatitis C Virus Infection

Australia, France, Germany, Korea, Republic of, Sweden, Taiwan, United Kingdom, United States, Canada, Mexico, Austria, Italy, Spain, Denmark, Argentina, Poland, Ireland, Greece, New Zealand
Bristol-Myers Squibb

Completed

Drug Interaction Oral Contraceptive Pill (OCP)

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

France, Germany, Italy, Japan, United States, Australia, Puerto Rico, Spain, New Zealand
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States

3

Subscribe